Compare Organon & Co. Common Stock (OGN) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Under Armour Inc Class A — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Under Armour Inc Class A trades at $4.65 (market cap $2.08B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Under Armour Inc Class A for 19 Days on average.
| OGN | UA | |
|---|---|---|
Market Cap | $3.62B | $2.08B |
Volume | 2,892,999 | 2,142,599 |
Sector | Health | Consumer Cyclical |
52-Week High | $13.81 | $7.88 |
52-Week Low | $5.70 | $3.96 |
Typical Hold Time | 0 Days | 19 Days |
Enterprise Value | $11.04B | $3.06B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Under Armour (UA) trades at $4.76, down 0.63% with a bullish technical signal despite negative profitability metrics. The company reported mixed quarterly earnings with two beats and one miss, while revenue declined to $4.9B in 2026 with a net loss of $492M. Analyst sentiment is divided with 40% buy ratings, though recent news highlights revenue guidance cuts and competitive pressures.
The outlook remains challenging with persistent revenue declines and negative margins offset by attractive valuation multiples. Investment opportunity lies in potential turnaround execution, while risks include sustained consumer demand weakness and execution missteps in a highly competitive athletic apparel market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
